Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous administration. It is used in the treatment of metastatic and advanced colorectal cancer, primarily in adult patients who have disease progression after standard therapies.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this chemotherapy agent for qualified healthcare providers and ensuring compliance with local regulations.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer.

Metastatic colorectal cancer: improves survival in patients with disease spread beyond the colon. Advanced colorectal cancer: provides disease control in patients with locally advanced disease. Colorectal cancer (first‑line therapy): used in combination with other agents for initial treatment of eligible patients.

Irinotecan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with anti‑emetics. - Fatigue: general tiredness experienced during treatment. - Alopecia: hair loss that may be temporary. - Anemia: decreased red blood cell count causing fatigue.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis or intestinal perforation: life‑threatening gastrointestinal complications. - Hepatotoxicity: liver enzyme elevations that may progress to liver injury. - Severe allergic reactions: anaphylaxis or hypersensitivity requiring immediate treatment. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Cardiotoxicity: rare heart rhythm abnormalities.

Before initiating therapy, clinicians should assess patient-specific factors and monitor for potential complications.

Monitor blood counts: perform regular complete blood count tests to detect neutropenia. Assess liver function: evaluate hepatic enzymes as irinotecan metabolism is liver‑dependent. Evaluate bowel status: screen for pre‑existing diarrhea or intestinal obstruction. Adjust dose in hepatic impairment: reduce dosage for patients with significant liver dysfunction. Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Irinotecan can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may reduce SN‑38 formation and therapeutic effect. - UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 exposure and risk of severe neutropenia. - Concurrent myelosuppressive agents: may cause additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding risk. - Drugs affecting gastrointestinal motility (e.g., loperamide): may alter diarrhea severity. - Other chemotherapy agents (e.g., oxaliplatin): adjust dosing and monitor for overlapping toxicities.